Skip to content

Clinical Efficacy and Safety Evaluation of Shiwu-Tuomin-Decoction in Children with Food Allergy

Clinical Efficacy and Safety Evaluation of Shiwu-Tuomin-Decoction in Children with Food Allergy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001631
Enrollment
Unknown
Registered
2025-09-01
Start date
2025-09-15
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Food allergy

Interventions

Intervention group:Shiwu-Tuomin-Decoction
Control group:Placebo

Sponsors

National Institute of TCM Constitution and Preventive Medicine Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 6 Years

Inclusion criteria

Inclusion criteria: (1) Meeting the diagnostic criteria for food allergy; (2) Meeting the diagnostic criteria for inherited special constitution in Traditional Chinese Medicine (TCM); (3) Either gender aged 3-6 years (inclusive); (4) Stable symptoms in all organ systems (skin/mucosa respiratory digestive nervous and circulatory systems) without medication requirement or where use of relief medications would not affect efficacy evaluation; (5) No use of any food allergy-related therapeutic drugs within 2 weeks prior to diagnosis; (6) Written informed consent obtained from parents or legal guardians.

Exclusion criteria

Exclusion criteria: (1) History of life-threatening food allergy reactions (e.g. anaphylactic shock syncope) or other food allergy symptoms (e.g. asthma abdominal pain vomiting dyspnea) that significantly impair daily life quality; (2) Requiring ongoing medication for symptom control in any organ system (skin/mucosa respiratory digestive nervous or circulatory systems) within 2 weeks prior to enrollment which may interfere with efficacy evaluation; (3) Symptoms attributable to other diseases (e.g. respiratory digestive or hematologic disorders); (4) Comorbidities including inflammatory bowel conditions indwelling catheters gastrostomy immunocompromised status post-cardiac/GI surgery critical illness or conditions requiring prolonged hospitalization; (5) Known hypersensitivity to any component of the investigational product; (6) Severe primary diseases affecting major organs (cardiac hepatic renal digestive or hematopoietic systems); (7) Inability to cooperate or participation in other drug trials within 1 month prior to screening; (8) Investigator-determined ineligibility for any clinical reason.

Design outcomes

Primary

MeasureTime frame
Desensitization rate;

Secondary

MeasureTime frame
Consortium for Food Allergy Research Systemic Allergic Reaction Grading System;Fecal Characteristics Evaluation;Serum Allergen-Specific Immunoglobulin E Testing;Physical Growth Level;Medication Scoring;Maximum tolerated dose in a single open food challenge;Time to Recurrence;Skin prick test;Total cumulative tolerated dose in a single open food challenge;Traditional Chinese Medicine Constitution Scoring;Childrens Sleep Habits Questionnaire;Serum Allergen-Specific Immunoglobulin G4 Testing;

Countries

China

Contacts

Public ContactQi Wang

National Institute of TCM Constitution and Preventive Treatment of Disease Wangqi Academy of Beijing University of Chinese Medicine

wangqi710@126.com13901003796

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026